Progression rate of neurological deficits in a 10-year cohort of SCA3 patients.
Spinocerebellar ataxia 3 is an untreatable CAG repeat expansion disorder whose natural history is not completely understood. Our aims were to describe the progression of neurological manifestations in a long-term cohort of spinocerebellar ataxia 3, and to verify if CAG expanded repeat, gender, and age at onset were associated with the rate of progression. Patients entered the study between 1998 and 2005 and were seen until 2007. On each visit, the validated NESSCA scale, an inventory of 18 neurological manifestations, was applied. Scores observed in each year of disease duration produced a Growth Curve, which was analyzed through the random coefficients model. Scores obtained in some individual items were described through multi-state Markov models. One hundred fifty-six patients (78 families) were recruited; 28 were lost, and 23 died. Mean (sd) ages at onset and at baseline were 32.8 (10.6) and 40.7 (12.8) years; median (range) expanded CAGn was 74 (67-85). Three hundred fifteen NESSCA evaluations were performed, comprising disease durations from zero to 34 years. The 105 patients who completed the study were seen over 5 (sd = 2.4) years at intervals of 2.5 (sd = 1.5) years. The trajectory of NESSCA obtained for the overall group increased by 1.26 points per year. This slope increased by 0.15 points per each additional CAG in the expanded repeat (p < 0.0002) and decreased by 0.03 points per each additional year of age at onset (p = 0.005). NESSCA worsened steadily, producing linear trajectories, which were faster among patients with longer expanded repeats (>74) and with lower ages at onset (<34 years).
Jardim
Laura Bannach
LB
Department of Internal Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil. ljardim@hcpa.ufrgs.br
Hauser
Lisiane
L
Kieling
Christian
C
Saute
Jonas Alex Morales
JA
Xavier
Renan
R
Rieder
Carlos Roberto Mello
CR
Monte
Thais Lampert
TL
Camey
Suzi
S
Torman
Vanessa Bielefeld Leotti
VB
D000328:Adult; D000367:Age Factors; D017668:Age of Onset; D002648:Child; D015331:Cohort Studies; D018450:Disease Progression; D005260:Female; D006801:Humans; D008137:Longitudinal Studies; D017827:Machado-Joseph Disease / Q000235:genetics* / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D018911:Trinucleotide Repeats / Q000235:genetics
Nat Genet. 1993 Jul;4(3):300-4
8358439
J Neurol. 2003 Feb;250(2):207-11
12574952
Stat Med. 1998 Oct 30;17(20):2395-403
9819835
Eur J Neurol. 2008 Apr;15(4):371-6
18312406
Mov Disord. 2009 Jul 15;24(9):1387-90
19441132
Am J Med Genet B Neuropsychiatr Genet. 2010 Jan 5;153B(1):132-40
19415691
Am J Med Genet B Neuropsychiatr Genet. 2008 Jun 5;147B(4):439-46
17948873
Brain. 1997 Dec;120 ( Pt 12):2141-8
9448569
Ann Hum Genet. 2008 Jan;72(Pt 1):57-64
17683516
J Neurol Sci. 1997 Feb 12;145(2):205-11
9094050
J Neurol Neurosurg Psychiatry. 1997 Oct;63(4):534-6
9343141
Arch Neurol. 2001 Jun;58(6):899-904
11405804
Ann Neurol. 1995 Oct;38(4):684-7
7574470
Brain. 1998 Apr;121 ( Pt 4):589-600
9577387
Ann Neurol. 1997 Dec;42(6):924-32
9403486
Neurology. 1998 Dec;51(6):1603-7
9855509
Ann Neurol. 1996 Apr;39(4):490-9
8619527
Nat Genet. 1994 Nov;8(3):221-8
7874163
Neuroepidemiology. 2010;34(3):163-70
20130417
Clin Genet. 2007 Dec;72(6):543-5
17894834